ADAR1 Capital Management »

Prothena shares owned by ADAR1 Capital Management

Quarter-by-quarter ownership of Prothena (PRTA) shares owned by ADAR1 Capital Management from 13F filings

Historical chart of ADAR1 Capital Management investment in Prothena

Tip: Access up to 7 years of quarterly data

All positions including Prothena held by ADAR1 Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Prothena by ADAR1 Capital Management

Quarter filed Position value Share count Share price at filing
2024-03-31 $148k 6.0k 24.77
2023-12-31 $222k 6.1k 36.34

More positions owned by ADAR1 Capital Management

Alnylam Pharmaceuticals (ALNY)
Ea Series Trust Alpha Arch 1-3 (BOXX)
Roivant Sciences SHS (ROIV)
Spdr S&p 500 Etf Tr Tr Unit Put Option (SPY)
Protagonist Therapeutics (PTGX)
Cytokinetics Com New (CYTK)
Keros Therapeutics (KROS)
Royalty Pharma Shs Class A (RPRX)
Bridgebio Pharma (BBIO)
Merrimack Pharmaceuticals In Com New
Ascendis Pharma A/s Sponsored Adr (ASND)
Arbutus Biopharma (ABUS)
Avrobio Ord (AVRO)
Beigene Sponsored Adr (BGNE)
Invesco Qqq Tr Unit Ser 1 Put Option (QQQ)

View all positions for ADAR1 Capital Management

Top funds holding Prothena

EcoR1 Capital
BlackRock
BlackRock
T. Rowe Price Associates
State Street Corporation
Palo Alto Investors
Armistice Capital
Vanguard Group
Siren
Henderson Group
Geode Capital Management
Dimensional Fund Advisors
Morgan Stanley
Boxer Capital
Rock Springs Capital Management

View all funds holding Prothena